252 related articles for article (PubMed ID: 22077621)
1. Natural killer cell engineering for cellular therapy of cancer.
Shook DR; Campana D
Tissue Antigens; 2011 Dec; 78(6):409-15. PubMed ID: 22077621
[TBL] [Abstract][Full Text] [Related]
2. Expansion and activation of natural killer cells for cancer immunotherapy.
Cho D; Campana D
Korean J Lab Med; 2009 Apr; 29(2):89-96. PubMed ID: 19411773
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15.
Gong W; Xiao W; Hu M; Weng X; Qian L; Pan X; Ji M
Tissue Antigens; 2010 Dec; 76(6):467-75. PubMed ID: 20670353
[TBL] [Abstract][Full Text] [Related]
4. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
Front Immunol; 2018; 9():150. PubMed ID: 29456538
[TBL] [Abstract][Full Text] [Related]
5. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation.
Wang X; Lee DA; Wang Y; Wang L; Yao Y; Lin Z; Cheng J; Zhu S
Clin Exp Immunol; 2013 Apr; 172(1):104-12. PubMed ID: 23480190
[TBL] [Abstract][Full Text] [Related]
6. Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21.
Jiang B; Wu X; Li XN; Yang X; Zhou Y; Yan H; Wei AH; Yan W
Cell Immunol; 2014 Jul; 290(1):10-20. PubMed ID: 24859012
[TBL] [Abstract][Full Text] [Related]
7. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
Front Immunol; 2021; 12():732135. PubMed ID: 34925314
[TBL] [Abstract][Full Text] [Related]
8. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
9. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
10. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.
Sahm C; Schönfeld K; Wels WS
Cancer Immunol Immunother; 2012 Sep; 61(9):1451-61. PubMed ID: 22310931
[TBL] [Abstract][Full Text] [Related]
11. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
12. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
[TBL] [Abstract][Full Text] [Related]
13. Expansion of NK Cells Using Genetically Engineered K562 Feeder Cells.
Phan MT; Lee SH; Kim SK; Cho D
Methods Mol Biol; 2016; 1441():167-74. PubMed ID: 27177665
[TBL] [Abstract][Full Text] [Related]
14. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
Lapteva N; Durett AG; Sun J; Rollins LA; Huye LL; Fang J; Dandekar V; Mei Z; Jackson K; Vera J; Ando J; Ngo MC; Coustan-Smith E; Campana D; Szmania S; Garg T; Moreno-Bost A; Vanrhee F; Gee AP; Rooney CM
Cytotherapy; 2012 Oct; 14(9):1131-43. PubMed ID: 22900959
[TBL] [Abstract][Full Text] [Related]
15. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
16. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
Zhang H; Cui Y; Voong N; Sabatino M; Stroncek DF; Morisot S; Civin CI; Wayne AS; Levine BL; Mackall CL
J Immunother; 2011 Mar; 34(2):187-95. PubMed ID: 21304401
[TBL] [Abstract][Full Text] [Related]
17. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
Mantesso S; Geerts D; Spanholtz J; Kučerová L
Front Immunol; 2020; 11():607131. PubMed ID: 33391277
[TBL] [Abstract][Full Text] [Related]
18. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
Fujisaki H; Kakuda H; Shimasaki N; Imai C; Ma J; Lockey T; Eldridge P; Leung WH; Campana D
Cancer Res; 2009 May; 69(9):4010-7. PubMed ID: 19383914
[TBL] [Abstract][Full Text] [Related]
19. [Expansion of human natural killer cells ex vivo].
Huang QS; Li Q; Huang Y; Shang P; Zhang MJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Dec; 24(12):1167-9. PubMed ID: 19068202
[TBL] [Abstract][Full Text] [Related]
20. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
Jiang W; Zhang C; Tian Z; Zhang J
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]